Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
50M
-
Number of holders
-
23
-
Total 13F shares, excl. options
-
6.48M
-
Shares change
-
-1.23M
-
Total reported value, excl. options
-
$63.2M
-
Value change
-
-$3M
-
Number of buys
-
15
-
Number of sells
-
-7
-
Price
-
$9.75
Significant Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q4 2017
28 filings reported holding KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share as of Q4 2017.
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) has 23 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.48M shares
of 50M outstanding shares and own 12.97% of the company stock.
Largest 10 shareholders include SV Health Investors, LLC (2.58M shares), RA CAPITAL MANAGEMENT, LLC (1.44M shares), EVENTIDE ASSET MANAGEMENT, LLC (709K shares), INTERWEST VENTURE MANAGEMENT CO (330K shares), INTERNATIONAL BIOTECHNOLOGY TRUST PLC (322K shares), Vivo Capital, LLC (300K shares), MILLENNIUM MANAGEMENT LLC (237K shares), NEXTHERA CAPITAL LP (181K shares), Vanguard Group Inc (118K shares), and RENAISSANCE TECHNOLOGIES LLC (88.7K shares).
This table shows the top 23 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.